Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis

References

• GranJHusbyGThe epidemiology of ankylosing spondylitisSemin Arthritis Rheum1993223193348511596
   PubMed Web of Science ®Google Scholar
• BraunJSieperJThe sacroiliac joint in the spondyloarthropathiesCurr Opin Rheumatol199682752878864578
   PubMedGoogle Scholar
• LeeJJunJJungSHigher prevalence of peripheral arthritis among ankylosing spondylitis patientsJ Korean Med Sci20021766967312378021
   PubMed Web of Science ®Google Scholar
• PetersMvan der Horst-BruinsmaIDijkmansBNurmohamedMCardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritisSemin Arthritis Rheum20043458559215609262
   PubMed Web of Science ®Google Scholar
• RosenbaumJAcute anterior uveitis and spondyloarthropathiesRheum Dis Clin North Am1992181431511561400
   PubMed Web of Science ®Google Scholar
• BaetenDDe KeyserFMielantsHVeysEAnkylosing spondylitis and bowel diseaseBest Pract Res Clin Rheumatol20021653754912406426
   PubMed Web of Science ®Google Scholar
• SmolenJBraunJDougadosMTreating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task forceAnn Rheum Dis20147361623749611
   PubMed Web of Science ®Google Scholar
• DoranMBrophySMacKayKPredictors of long-term outcome in ankylosing spondylitisJ Rheumatol20033031632012563688
   PubMed Web of Science ®Google Scholar
• SongIPoddubnyyDRudwaleitMSieperJBenefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugsArthritis Rheum20085892993818383378
   PubMed Web of Science ®Google Scholar
• ChenJLiuCLinJMethotrexate for ankylosing spondylitisCochrane Database Syst Rev2006CD00452417054209
   PubMed Web of Science ®Google Scholar
• CleggDRedaDAbdellatifMComparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative studyArthritis Rheum1999422325232910555027
   PubMed Web of Science ®Google Scholar
• HaibelHFendlerCListingJCallhoffJBraunJSieperJEfficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomized, placebo-controlled short-term trialAnn Rheum Dis20147324324623625982
   PubMed Web of Science ®Google Scholar
• BrandtJHaibelHCornelyDSuccessful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximabArthritis Rheum2000431346135210857793
   PubMed Web of Science ®Google Scholar
• BraunJBrandtJListingJTreatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trialLancet20023591187119311955536
   PubMed Web of Science ®Google Scholar
• GraingerRHarrisonAAInfliximab in the treatment of ankylosing spondylitisBiologics2007116317119707326
   PubMedGoogle Scholar
• BraunJBaraliakosXListingJSieperJDecreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanerceptArthritis Rheum2005522447245116052578
   PubMed Web of Science ®Google Scholar
• BraunJBrandtJListingATwo year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitisAnn Rheum Dis20056422923415388511
   PubMed Web of Science ®Google Scholar
• BraunJBaraliakosXListingJPersistent clinical efficacy and safety of anti-tumour necrosis factor-α therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of responseAnn Rheum Dis20086734034517967831
   PubMed Web of Science ®Google Scholar
• van der HeijdeDDijkmansBGeusensPEfficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)Arthritis Rheum20055258259115692973
   PubMed Web of Science ®Google Scholar
• HeldmannFBrandtJvan der Horst-BruinsmaIEThe European Ankylosing Spondylitis Infliximab Cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximabClin Exp Rheumatol20112967268021906431
   PubMed Web of Science ®Google Scholar
• VenetsanopoulouAIVoulgariPVAlamanosYPapadopoulosCGMarkatseliTEDrososAAPersistent clinical response of infliximab treatment, over a 4-year period in ankylosing spondylitisRheumatol Int20072793593917357804
   PubMed Web of Science ®Google Scholar
• MielantsHVeysECuvelierCde VosMCourse of gut inflammation in spondylarthropathies and therapeutic consequencesBaillieres Clin Rheumatol1996101471648674145
   PubMed Web of Science ®Google Scholar
• BraunJBaraliakosXListingJDifferences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor α agentsArthritis Rheum20075763964717471540
   PubMed Web of Science ®Google Scholar
• VisvanathanSvan der HeijdeDDeodharAEffects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitisAnn Rheum Dis20096817518218495735
   PubMed Web of Science ®Google Scholar
• ArendsSSpoorenbergAHoutmanPThe effect of three years of TNFα blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort studyArthritis Res Ther201214R9822546520
   PubMed Web of Science ®Google Scholar
• ArendsSvan der VeerEKallenbergCGBrouwerESpoorenbergABaseline predictors of response to TNF-α blocking therapy in ankylosing spondylitisCurr Opin Rheumatol20122429029822418743
   PubMed Web of Science ®Google Scholar
• ArendsSBrouwerEvan der VeerEBaseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort studyArthritis Res Ther201113R9421689401
   PubMed Web of Science ®Google Scholar
• VastesaegerNvan der HeijdeDInmanRDPredicting the outcome of ankylosing spondylitis therapyAnn Rheum Dis20117097398121402563
   PubMed Web of Science ®Google Scholar
• MörckBPulleritsRGeijerMBremellTForsblad-d’EliaHInfliximab dose reduction sustains the clinical treatment effect in active HLAB27 positive ankylosing spondylitis: a two-year pilot studyMediators Inflamm2013201328984524089587
   PubMed Web of Science ®Google Scholar
• BaraliakosXListingJBrandtJClinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximabArthritis Res Ther20057R439R44415899030
   PubMed Web of Science ®Google Scholar
• BrandtJListingJHaibelHLong-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitisRheumatology (Oxford)20054434234815561737
   PubMed Web of Science ®Google Scholar
• PlasenciaCPascual-SalcedoDNuñoLInfluence of immunogenicity on the efficacy of long-term treatment of spondyloarthritis with infliximabAnn Rheum Dis2012711955196022563028
   PubMed Web of Science ®Google Scholar
• KneepkensEWeiJNurmohamedMYeoKExtended report: immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-upAnn Rheum Dis20157439640124326011
   PubMed Web of Science ®Google Scholar
• BarkhamNKeenHCoatesLClinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitisArthritis Rheum20096094695419333933
   PubMed Web of Science ®Google Scholar
• LouieGHWardMMMeasurement and treatment of radiographic progression in ankylosing spondylitis: lessons learned from observational studies and clinical trialsCurr Opin Rheumatol20142614515024389865
   PubMed Web of Science ®Google Scholar
• van der HeijdeDLandewéRBaraliakosXRadiographic findings following two years of infliximab therapy in patients with ankylosing spondylitisArthritis Rheum2008583063307018821688
   PubMed Web of Science ®Google Scholar
• BaraliakosXListingJBrandtJRadiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-α antibody infliximabRheumatology (Oxford)2007461450145317623745
   PubMed Web of Science ®Google Scholar
• BaraliakosXHaibelHListingJSieperJBraunJContinuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitisAnn Rheum Dis20147371071523505240
   PubMed Web of Science ®Google Scholar
• HaroonNInmanRLearchTThe impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitisArthritis Rheum2013652645245423818109
   PubMed Web of Science ®Google Scholar
• TongQCaiQde MooijTAdverse events of anti-tumor necrosis factor α therapy in ankylosing spondylitisPLoS One201510e011989725764452
   PubMed Web of Science ®Google Scholar
• GibofskyAPalmerWKeystoneESafety profiles of disease-modifying anti-rheumatic drugs and biologics in patients with rheumatoid arthritis: observations from the RADIUS registryArthritis Rheum200960Suppl 101593
   Google Scholar
• CurtisJChenLCushJThe risk for hospitalized and outpatient infections related to anti-TNF therapy and newer biologicsArthritis Rheum200960Suppl 102059
   Google Scholar
• DixonWGWatsonKLuntMHyrichKLSilmanAJSymmonsDPRates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics RegisterArthritis Rheum2006542368237616868999
   PubMed Web of Science ®Google Scholar
• TubachFSalmonDRavaudPRisk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registryArthritis Rheum2009601884189419565495
   PubMed Web of Science ®Google Scholar
• WesthovensRYocumDHanJThe safety of infliximab, compared with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trialArthritis Rheum2006541075108616572442
   PubMed Web of Science ®Google Scholar
• ListingJStrangfeldAKarySInfections in patients with rheumatoid arthritis treated with biologic agentsArthritis Rheum2005523403341216255017
   PubMed Web of Science ®Google Scholar
• StrangfeldAListingJHerzerPRisk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agentsJAMA200930173774419224750
   PubMed Web of Science ®Google Scholar
• KeystoneEAdvances in targeted therapy: safety of biological agentsAnn Rheum Dis200362Suppl 2ii34ii3614532146
   PubMedGoogle Scholar
• BalkwillFMantovaniACancer and inflammation: implications for pharmacology and therapeuticsClin Pharmacol Ther20108740140620200512
   PubMed Web of Science ®Google Scholar
• MoulisGSommetABénéJCancer risk of anti-TNF-α at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analysesPLOS One20127e4899123155441
   PubMed Web of Science ®Google Scholar
• MarietteXMatucci-CerinicMPavelkaKMalignancies associated with tumor necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysisAnn Rheum Dis2011701895190421885875
   PubMed Web of Science ®Google Scholar
• BaecklundEEkbomASparénPFelteliusNKlareskogLDisease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control studyBMJ19983171801819665898
   PubMed Web of Science ®Google Scholar
• AsklingJFahrbachKNordstromBRossSSchmidCHSymmonsDCancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level dataPharmacoepidemiol Drug Saf20112011913021254282
   PubMed Web of Science ®Google Scholar
• BaecklundEIliadouAAsklingJAssociation of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritisArthritis Rheum20065469270116508929
   PubMed Web of Science ®Google Scholar
• MagnanoMRobinsonWGenoveseMDemyelination and inhibition of tumor necrosis factor (TNF)Clin Exp Rheumatol200422S134S14015552527
   PubMed Web of Science ®Google Scholar
• MoulisGSommetALapeyre-MestreMMontastrucJIs the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance databaseRheumatology (Oxford)2014531864187124899660
   PubMed Web of Science ®Google Scholar
• BénéJMoulisGAuffretMFessierCLefevreGGautierSTumor necrosis factor antagonists and alopecia: a case/non case in a nationwide pharmacovigilance databaseArthritis Rheum201264S788
   PubMedGoogle Scholar
• HarrisonMDixonWWatsonKRates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor αtherapy: results from the British Society for Rheumatology Biologics RegisterAnn Rheum Dis20096820921518385277
   PubMed Web of Science ®Google Scholar